In participants 18 years or older who have one F508del mutation and one minimal function mutation, some will receive VX-659, ivacaftor and tezacaftor, and some will receive placebo.
In participants with two F508del mutations, some will receive VX-659, ivacaftor and tezacaftor and some will receive placebo and ivacaftor and tezacaftor.
https://clinicaltrials.gov/ct2/show/NCT03224351?cond=cystic+fibrosis&intr=VX-659&lead=Vertex&rank=2
In participants with two F508del mutations, some will receive VX-659, ivacaftor and tezacaftor and some will receive placebo and ivacaftor and tezacaftor.
https://clinicaltrials.gov/ct2/show/NCT03224351?cond=cystic+fibrosis&intr=VX-659&lead=Vertex&rank=2